Talk:Sio Gene Therapies

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Some proposed changes[edit]

Update logo to new one. New logo source: http://axovant.com/wp-content/uploads/2017/04/Axovant_Logo_RGB_For-Website.png

Update headquarters to Switzerland. Source: https://www.crunchbase.com/organization/axovant-sciences 50.75.206.4 (talk) 16:59, 12 April 2017 (UTC)[reply]

Crunchbase is not a reliable source. Will try to get to the logo later. Interesting way to do it.... Jytdog (talk) 17:18, 12 April 2017 (UTC)[reply]
Thank you, how about the SEC filings? https://www.sec.gov/Archives/edgar/data/1636050/000163605017000011/a12311610qaxovant.htm ... — Preceding unsigned comment added by 50.75.206.4 (talk) 21:39, 17 April 2017 (UTC)[reply]

Following up on both of these changes.[edit]

The headquarters is now Switzerland as shown/cited here: http://axovant.com/about/contact-us/ as well as with the SEC filings. Thanks! 50.75.206.4 (talk) 15:08, 11 May 2017 (UTC)[reply]

According to its most recent 10K it is incorporated in Bermuda. 10-K. Jytdog (talk) 02:55, 12 May 2017 (UTC)[reply]

can you update the company logo here: http://axovant.com/wp-content/uploads/2017/04/Axovant_Logo_Neurology_RGB_For-Website.png 50.75.206.4 (talk) 19:42, 23 May 2017 (UTC)[reply]

Thanks for the ping. I don't mess around with images -- too much of a pain in the butt. Somebody from your company can upload it at the commons, here - and whoever does that should be sure to give the appropriate license, etc, so that we can use it. Jytdog (talk) 19:50, 23 May 2017 (UTC)[reply]
@Jytdog: Thanks about the image. AXON’s most recent filing states its Address of principal executive office is in the UK (there are no operations in Bermuda) This is also on the AXO website. Its Corporate Headquarters however, are in Switzerland, is as described on page 7, note 1 of the 10Q: https://www.sec.gov/Archives/edgar/data/1636050/000163605017000011/a12311610qaxovant.htm

http://axovant.com/about/contact-us/. Does this help? Thanks again! 50.75.206.4 (talk) 19:55, 23 May 2017 (UTC)[reply]

The SEC filing makes it clear that the company was incorporated in Bermuda and its principal executive offices are there. It is right there on the cover page. Jytdog (talk) 19:58, 23 May 2017 (UTC)[reply]
@Jytdog: The principal executive office was recently changed, see most recent 8-K filing https://www.sec.gov/Archives/edgar/data/1636050/000110465917023139/a17-11115_48k.htm50.75.206.4 (talk) 20:06, 23 May 2017 (UTC)[reply]
Note: as the most recent 10-K filing (presented by IP on their talk page) does support the change of headquarters, but notes that the place of incorporation remains in Bermuda, I have noted both facts in the article as a compromise. Altamel (talk) 02:07, 21 June 2017 (UTC)[reply]
@Jytdog:

Here is Axovant’s new logo. File here:

new Axovant logo

Also here are other sources of the Axovant HQ change: http://www.barrons.com/quote/stock/us/xnys/axon/company-people https://markets.ft.com/data/equities/tearsheet/profile?s=AXON:NYQ http://money.cnn.com/quote/forecast/forecast.html?symb=AXON

Thanks! 50.75.206.4 (talk) 14:19, 14 June 2017 (UTC)[reply]

Some proposed changes[edit]

I have COI with this company as an employee, but would like to propose the following changes:

1. Information to be added or removed: change “pharmaceutical” to “biopharmaceutical”, change "small molecule drugs" to "gene therapies", and add "and neuromuscular" after "neurological" in first sentence.

a. Explanation of issue: Axovant has made a significant pivot into gene therapies since June 2018 with the additions of gene therapies for Parkinson’s Disease, oculopharyngeal muscular dystrophies (which is a neuromuscular disease, not just a neurological disease) and other diseases, this makes the company much more of a biotechnology and pharmaceutical company, so a biopharmaceutical company

b. References supporting change: https://endpts.com/picking-up-the-pieces-left-from-an-alzheimers-implosion-axovant-is-starting-over-by-diving-into-gene-therapy/, https://endpts.com/focused-on-rebuilding-the-pipeline-axovants-new-crew-assembles-another-preclinical-gene-therapy-deal/, https://www.statnews.com/2018/06/06/axovant-will-walll-street-love-again/, https://www.biospace.com/article/axovant-licenses-gene-therapy-for-parkinson-s-disease-from-oxford-biomedica/, https://www.fiercebiotech.com/biotech/axovant-pivots-new-gene-therapy-license-spark-co-founder-as-cto


2. Suggested addition of additional language describing the pivot: after the last sentence “Since joining the company as CEO, Pavan Cheruvu has made a pivot for the company into gene therapies, with a series of in-licensing deals. The first, a gene therapy now known as AXO-Lenti-PD to treat Parkinson’s disease, was licensed from Oxford Biomedica in June 2018. In July 2018, Axovant announced a second deal with Benitec for the rights to a gene therapy to treat oculopharyngeal muscular dystrophy (OPMD), along with five additional programs to treat conditions such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.”

a. Explanation of issue: The current article doesn’t reflect significant changes in Axovant’s pipeline made since June 2018.

b. References supporting change (same as above change): https://endpts.com/picking-up-the-pieces-left-from-an-alzheimers-implosion-axovant-is-starting-over-by-diving-into-gene-therapy/, https://endpts.com/focused-on-rebuilding-the-pipeline-axovants-new-crew-assembles-another-preclinical-gene-therapy-deal/, https://www.statnews.com/2018/06/06/axovant-will-walll-street-love-again/, https://www.biospace.com/article/axovant-licenses-gene-therapy-for-parkinson-s-disease-from-oxford-biomedica/, https://www.fiercebiotech.com/biotech/axovant-pivots-new-gene-therapy-license-spark-co-founder-as-cto

144.121.125.3 (talk) 21:49, 19 October 2018 (UTC)[reply]

I've noticed that the changes suggested by different IP editor's over the past year have been made without offering the required disclosures (or if they have been, they are not easily located or placed in a central location where others may access them, such as this talk page). The IP editor needs to WP:DISCLOSE the nature of their COI and whether or not they've been paid for their suggestions before any further changes can be made.  Spintendo  00:41, 20 October 2018 (UTC)[reply]

Resubmitting Proposed Changes with Appropriate Disclosure[edit]

I have COI with this company as an employee, but would like to propose the following changes:

Extended content

1. Information to be added or removed: change “pharmaceutical” to “biopharmaceutical”, change "small molecule drugs" to "gene therapies", and add "and neuromuscular" after "neurological" in first sentence.

a. Explanation of issue: Axovant has made a significant pivot into gene therapies since June 2018 with the additions of gene therapies for Parkinson’s Disease, oculopharyngeal muscular dystrophies (which is a neuromuscular disease, not just a neurological disease) and other diseases, this makes the company much more of a biotechnology and pharmaceutical company, so a biopharmaceutical company. Axovant has also publicly announced the discontinuation of their small-molecule pipeline.

b. References supporting change: [1], [2], [3], [4], [5], [6], [7], [8], [9]


2. Suggested addition of additional language describing the pivot: after the last sentence “Since joining the company as CEO, Pavan Cheruvu has made a pivot for the company into gene therapies, with a series of in-licensing deals. The first, a gene therapy now known as AXO-Lenti-PD to treat Parkinson’s disease, was licensed from Oxford Biomedica in June 2018. In July 2018, Axovant announced a second deal with Benitec for the rights to a gene therapy to treat oculopharyngeal muscular dystrophy (OPMD), along with five additional programs to treat conditions such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.”

a. Explanation of issue: The current article doesn’t reflect significant changes in Axovant’s pipeline made since June 2018.

b. References supporting change (same as the above change): [10], [11], [12], [13], [14], [15], [16], [17], [18]

References

  1. ^ https://endpts.com/picking-up-the-pieces-left-from-an-alzheimers-implosion-axovant-is-starting-over-by-diving-into-gene-therapy/
  2. ^ https://endpts.com/focused-on-rebuilding-the-pipeline-axovants-new-crew-assembles-another-preclinical-gene-therapy-deal/
  3. ^ https://www.statnews.com/2018/06/06/axovant-will-walll-street-love-again/
  4. ^ https://www.biospace.com/article/axovant-licenses-gene-therapy-for-parkinson-s-disease-from-oxford-biomedica/
  5. ^ https://www.fiercebiotech.com/biotech/axovant-pivots-new-gene-therapy-license-spark-co-founder-as-cto
  6. ^ http://investors.axovant.com/news-releases/news-release-details/axovant-reports-results-exploratory-phase-2-clinical-study
  7. ^ https://www.fiercebiotech.com/biotech/axovant-dumps-nelotanserin-retreat-from-small-molecule-r-d
  8. ^ http://www.pmlive.com/pharma_news/axovant_drops_last_legacy_drug_to_focus_on_gene_therapies_1272411
  9. ^ https://scrip.pharmaintelligence.informa.com/SC124320/Axovant-Closes-Chapter-On-Failed-SecondRate-Small-Molecule-Strategy
  10. ^ https://endpts.com/picking-up-the-pieces-left-from-an-alzheimers-implosion-axovant-is-starting-over-by-diving-into-gene-therapy/
  11. ^ https://endpts.com/focused-on-rebuilding-the-pipeline-axovants-new-crew-assembles-another-preclinical-gene-therapy-deal/
  12. ^ https://www.statnews.com/2018/06/06/axovant-will-walll-street-love-again/
  13. ^ https://www.biospace.com/article/axovant-licenses-gene-therapy-for-parkinson-s-disease-from-oxford-biomedica/
  14. ^ https://www.fiercebiotech.com/biotech/axovant-pivots-new-gene-therapy-license-spark-co-founder-as-cto
  15. ^ http://investors.axovant.com/news-releases/news-release-details/axovant-reports-results-exploratory-phase-2-clinical-study
  16. ^ https://www.fiercebiotech.com/biotech/axovant-dumps-nelotanserin-retreat-from-small-molecule-r-d
  17. ^ http://www.pmlive.com/pharma_news/axovant_drops_last_legacy_drug_to_focus_on_gene_therapies_1272411
  18. ^ https://scrip.pharmaintelligence.informa.com/SC124320/Axovant-Closes-Chapter-On-Failed-SecondRate-Small-Molecule-Strategy

144.121.125.3 (talk) 16:56, 11 December 2018 (UTC)[reply]

Reply 18-DEC-2018[edit]

  Unable to review edit request  

  1. Thank you for submitting the required disclosure. This has been moved to the top of the talk page, and does not need to be placed in each proposal.
  2. Unfortunately, your edit request could not be reviewed because it is unclear which references are connected to which claim statements are made in the text of your proposal. When proposing edit requests, it is important to highlight in the text which specific sources are doing the referencing for each claim by placing ref tags at the precise locations where the referenced claims are made. The point of an inline citation is to allow the reviewer and readers to check that the material is sourced; that point is lost if the citation's note number is not clearly placed. Note the example below:
☒N INCORRECT

The Sun's diameter is 864,337.3 miles, while the Moon's diameter is 2,159 miles. The Sun's temperature is 5,778 degrees Kelvin.

References supporting these changes:

[1][2][3]

In the example above there are three references provided, but the claim statements do not indicate which reference applies where. Your edit request similarly does not specify where the references you have provided are to be placed, as the ref tags have instead been placed all at the end of the request, not within the text of the proposal itself. These links between material and their source references must be more clearly made, as shown in the next example below:

checkY CORRECT

The Sun's diameter is 864,337.3 miles,[1] while the Moon's diameter is 2,159 miles.[2] The Sun's temperature is 5,778 degrees Kelvin.[3]

References

  1. ^ Sjöblad, Tristan. The Sun. Academic Press, 2018, p. 1.
  2. ^ Duvalier, Gabrielle. "Size of the Moon", Scientific American, 51(78):46.
  3. ^ Uemura, Shū. The Sun's Heat. Academic Press, 2018, p. 2.

In the example above, the links between the provided references and their claim statements are perfectly clear. Kindly reformulate your edit request so that it aligns more with the second example above, and feel free to re-submit that edit request at your earliest convenience. Regards,  Spintendo  15:38, 18 December 2018 (UTC)[reply]

Resubmitting proposed changes with appropriate formatting[edit]

I have a COI with the company as an employee, but would like to propose the following changes for consideration:

1. Change "small molecule drugs" in the first sentence to "gene therapies" because the company has made a significant pivot into gene therapies since June 2018 with the additions of gene therapies for Parkinson’s Disease[1][2][3][4], oculopharyngeal muscular dystrophy [5], GM1 gangliosidosis and GM2 gangliosidosis (also known as Tay-Sachs and Sandhoff diseases) [6][7]

2. Add "and neuromuscular" after "neurological" in the first sentence, since the company has added a therapy for oculopharyngeal muscular dystrophy[8], a neuromuscular disease[9], to its pipeline

3. Change the second sentence in the fourth paragraph from "As of 2016 Axovant was developing it as a treatment for Lewy body dementia" to "Axovant was developing it as a treatment for Lewy body dementia [10], but discontinued its development following a clinical trial that did not meet its primary endpoint [11][12]

4. Following the last paragraph, add "Since joining the company as CEO, Pavan Cheruvu has made a pivot for the company into gene therapies, with a series of in-licensing deals. The first, a gene therapy now known as AXO-Lenti-PD to treat Parkinson’s disease, was licensed from Oxford Biomedica in June 2018[13][14][15][16]. In July 2018, Axovant announced a second deal with Benitec for the rights to a gene therapy to treat oculopharyngeal muscular dystrophy (OPMD), along with five additional programs to treat conditions such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.[17] In December 2018, Axovant added two additional gene therapy programs to treat GM1 gangliosidosis and Tay-Sachs and Sandhoff diseases [18][19].”

144.121.125.3 (talk) 22:22, 14 January 2019 (UTC)[reply]

References

  1. ^ https://endpts.com/picking-up-the-pieces-left-from-an-alzheimers-implosion-axovant-is-starting-over-by-diving-into-gene-therapy/
  2. ^ https://www.statnews.com/2018/06/06/axovant-will-walll-street-love-again/
  3. ^ https://www.biospace.com/article/axovant-licenses-gene-therapy-for-parkinson-s-disease-from-oxford-biomedica/
  4. ^ https://www.fiercebiotech.com/biotech/axovant-pivots-new-gene-therapy-license-spark-co-founder-as-cto
  5. ^ https://endpts.com/focused-on-rebuilding-the-pipeline-axovants-new-crew-assembles-another-preclinical-gene-therapy-deal/
  6. ^ https://www.biospace.com/article/axovant-licenses-two-gene-therapies-aimed-at-tay-sachs-and-sandhoff-disease/
  7. ^ https://www.fiercebiotech.com/biotech/axovant-buys-more-gene-therapies-setting-it-up-for-a-busy-19
  8. ^ https://endpts.com/focused-on-rebuilding-the-pipeline-axovants-new-crew-assembles-another-preclinical-gene-therapy-deal/
  9. ^ https://rarediseases.org/rare-diseases/oculopharyngeal-muscular-dystrophy/
  10. ^ https://www.reuters.com/article/us-axovant-sciences-dementia-idUSKCN0XP2IL
  11. ^ https://www.fiercebiotech.com/biotech/axovant-dumps-nelotanserin-retreat-from-small-molecule-r-d
  12. ^ https://www.biospace.com/article/axovant-abandons-another-dementia-drug-after-failed-trial/
  13. ^ https://endpts.com/picking-up-the-pieces-left-from-an-alzheimers-implosion-axovant-is-starting-over-by-diving-into-gene-therapy/
  14. ^ https://www.statnews.com/2018/06/06/axovant-will-walll-street-love-again/
  15. ^ https://www.biospace.com/article/axovant-licenses-gene-therapy-for-parkinson-s-disease-from-oxford-biomedica/
  16. ^ https://www.fiercebiotech.com/biotech/axovant-pivots-new-gene-therapy-license-spark-co-founder-as-cto
  17. ^ https://endpts.com/focused-on-rebuilding-the-pipeline-axovants-new-crew-assembles-another-preclinical-gene-therapy-deal/
  18. ^ https://www.biospace.com/article/axovant-licenses-two-gene-therapies-aimed-at-tay-sachs-and-sandhoff-disease/
  19. ^ https://www.fiercebiotech.com/biotech/axovant-buys-more-gene-therapies-setting-it-up-for-a-busy-19

Reply 14-JAN-2019[edit]

  Unable to review edit request   Although you have placed the ref tags in the appropriate places (thank you for that) the provided references which you have supplied are still not formatted correctly.[a] The citation style predominantly used by the Axovant Sciences article is Citation Style 1 (CS1). The citation style used in your edit request consists of bare URL's.[b] Any requested edit of yours which may be implemented will need to resemble the current style already in use in the article – in this case, CS1. (See WP:CITEVAR.) In the extended section below titled Citation style, I have illustrated two examples: one showing how the edit request was submitted, and another showing how requests should be submitted in the future:

Citation style
Bare URL-style formatting:

The Sun's diameter is 864,337.3 miles,<ref>https://www.booksource.com</ref> while the Moon's diameter is 2,159 miles.<ref>https://www.journalsource.com</ref> The Sun's temperature is 5,778 degrees Kelvin.<ref>https://www.websource.com</ref>

Displays as:

The Sun's diameter is 864,337.3 miles,[1] while the Moon's diameter is 2,159 miles.[2] The Sun's temperature is 5,778 degrees Kelvin.[3]


References

1. https://www.booksource.com
2. http://www.journalsource.com
3. http://www.websource.com

In the example above there are three URL's provided with the claim statements, but these URL's have not been placed using Citation Style 1, which is the style predominantly used by the Axovant Sciences article. Using this style, the WikiFormatted text would resemble the following:

CS1-style formatting:

The Sun's diameter is 864,337.3 miles,<ref>{{cite book|last1=Sjöblad|first1=Tristan|title=The Sun|url=http://www.booksource.com|publisher=Academic Press|date=2018|page=1}}</ref> while the Moon's diameter is 2,159 miles.<ref>{{cite journal|last1=Duvalier|first1=Gabrielle|title=Size of the Moon|journal=Scientific American|issue=78|volume=51|url=http://www.journalsource.com|date=2018|page=46}}</ref> The Sun's temperature is 5,778 degrees Kelvin.<ref>{{cite web|last1=Uemura|first1=Shu|title=The Sun's Heat|url=http://www.websource.com|publisher=Academic Press|date=2018|page=2}}</ref>

Displays as:

The Sun's diameter is 864,337.3 miles,[1] while the Moon's diameter is 2,159 miles.[2] The Sun's temperature is 5,778 degrees Kelvin.[3]

References

  1. ^ Sjöblad, Tristan. The Sun. Academic Press, 2018, p. 1.
  2. ^ Duvalier, Gabrielle. "Size of the Moon", Scientific American, 51(78):46.
  3. ^ Uemura, Shū. The Sun's Heat. Academic Press, 2018, p. 2.

In the example above the references have been formatted according to Citation Style 1, which shows the author, the source's name, date, etc., all information which is lost when only the links are provided. As Wikipedia is a volunteer project, larger edit requests such yours are generally expected to have this formatting done before the request is submitted for review.

Kindly rewrite your edit request so that it aligns more with the second example shown in the collapsed section above, and feel free to re-submit that edit request at your earliest convenience. If you have any questions about this formatting please don't hesitate to ask myself or another editor. Regards,  Spintendo  07:36, 15 January 2019 (UTC)[reply]

Notes

  1. ^ The fault for this formatting error most likely originates from the edit request prompts which are used with the template. These prompts ask the editor to "supply the URL of any references used". While this omission of information is not the fault of the requesting COI editor, it nevertheless remains their responsibility to supply the references formatted in the style used with the article.
  2. ^ The use of bare URLs as references is a style which is acceptable for use in Wikipedia. However, general practice dictates that the style already in use for an article be the one that is subsequently used for all future additions unless changed by editorial consensus.[1]

References

  1. ^ "WP:CITEVAR - Wikipedia:Citing sources". Wikipedia. 20 October 2018. Retrieved 22 October 2018. It is normal practice to defer to the style used by the first major contributor or adopted by the consensus of editors already working on the page, unless a change in consensus has been achieved. If the article you are editing is already using a particular citation style, you should follow it.

Another attempt at submission of proposed changes[edit]

I have a COI with the company as an employee, but would like to propose the following changes for consideration:

1. Change "small molecule drugs" in the first sentence to "gene therapies" because the company has made a significant pivot into gene therapies since June 2018 with the additions of gene therapies for Parkinson’s Disease[1][2], oculopharyngeal muscular dystrophy[3], GM1 gangliosidosis and GM2 gangliosidosis (also known as Tay-Sachs and Sandhoff diseases)[4][5]

2. Add "and neuromuscular" after "neurological" in the first sentence, since the company has added a therapy for oculopharyngeal muscular dystrophy[3], a neuromuscular disease[6], to its pipeline

3. Change the second sentence in the fourth paragraph from "As of 2016 Axovant was developing it as a treatment for Lewy body dementia" to "Axovant was developing it as a treatment for Lewy body dementia[7], but discontinued its development following the completion of a clinical trial that did not meet its primary endpoint[8][9]."

4. Following the last paragraph, add "Since joining the company as CEO, Pavan Cheruvu has made a pivot for the company into gene therapies, with a series of in-licensing deals. The first, a gene therapy now known as AXO-Lenti-PD to treat Parkinson’s disease, was licensed from Oxford Biomedica in June 2018[10][11]. In July 2018, Axovant announced a second deal with Benitec for the rights to a gene therapy to treat oculopharyngeal muscular dystrophy (OPMD), along with five additional programs to treat conditions such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.[3] In December 2018, Axovant added two additional gene therapy programs to treat GM1 gangliosidosis and Tay-Sachs and Sandhoff diseases [4][5].”

144.121.125.3 (talk) 20:49, 15 January 2019 (UTC)[reply]

References

  1. ^ Carroll, John (6 June 2018). "Picking up the pieces left from an Alzheimer's implosion, Axovant is starting over by diving into gene therapy". Endpoints.
  2. ^ Adams, Ben (6 June 2018). "Axovant pivots with new gene therapy, Spark co-founder as CTO". FierceBiotech.
  3. ^ a b c Carroll, John (9 July 2018). "Focused on rebuilding the pipeline, Axovant's new crew assembles another preclinical gene therapy deal". Endpoints.
  4. ^ a b Keown, Alex (14 December 2018). "Axovant Licenses Two Gene Therapies Aimed at Tay-Sachs and Sandhoff Disease". BioSpace.
  5. ^ a b Taylor, Nick Paul (14 December 2018). "Axovant buys more gene therapies, setting it up for a busy 2019". FierceBiotech.
  6. ^ "Oculopharyngeal Muscular Dystrophy". National Organization for Rare Diseases. 2012.
  7. ^ Grover, Natalie (28 Apr 2016). "Acadia drug approval could clear way for Axovant dementia therapy". Reuters.
  8. ^ Taylor, Nick Paul (10 December 2018). "Axovant dumps nelotanserin in retreat from small molecule R&D". FierceBiotech.
  9. ^ Terry, Mark (10 December 2018). "Axovant Abandons Another Dementia Drug After Failed Trial". BioSpace.
  10. ^ Terry, Mark (6 June 2018). "Axovant Licenses Gene Therapy for Parkinson's Disease from Oxford BioMedica". BioSpace.
  11. ^ Garde, Damian (6 June 2018). "Months after a monstrous blowup, a closely watched biotech sets its sights on gene therapy". STAT News. {{cite news}}: Italic or bold markup not allowed in: |newspaper= (help)

Reply 15-JAN-2019[edit]

Below you will see where proposals from your request have been quoted with reviewer decisions and feedback inserted underneath, either accepting, declining or otherwise commenting upon your proposal(s). Please read the enclosed notes within the proposal review section below for information on each request.  Spintendo  21:42, 15 January 2019 (UTC)[reply]

Proposal review 15-JAN-2019

Change "small molecule drugs" in the first sentence to "gene therapies" because the company has made a significant pivot into gene therapies since June 2018
 Approved.[note 1]


Add "and neuromuscular" after "neurological" in the first sentence.
 Approved.[note 2]


Axovant was developing it as a treatment for Lewy body dementia, but discontinued its development following the completion of a clinical trial that did not meet its primary endpoint.
Clarification needed.[note 3]


Since joining the company as CEO, Pavan Cheruvu has made a pivot for the company into gene therapies, with a series of in-licensing deals. The first, a gene therapy now known as AXO-Lenti-PD to treat Parkinson’s disease, was licensed from Oxford Biomedica in June 2018.
Clarification needed.[note 4]


In July 2018, Axovant announced a second deal with Benitec for the rights to a gene therapy to treat oculopharyngeal muscular dystrophy (OPMD), along with five additional programs to treat conditions such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
Clarification needed.[note 5]


In December 2018, Axovant added two additional gene therapy programs to treat GM1 gangliosidosis and Tay-Sachs and Sandhoff diseases.
 Approved.[note 6]


___________

  1. ^ Both entries are now listed. If the company no longer "develops" small molecule drugs, then this ought to be explained later in the article.
  2. ^ In addition to both of these terms being listed, the qualification that the company develops these agents in tandem with "other pharmaceutical companies" was mentioned in order to validate the fact that the company does not develop these agents on their own.
  3. ^ This part of the edit request proposal requires clarification because it is unclear what is meant by the words primary endpoint.
  4. ^ This part of the edit request proposal requires clarification because it is unclear what is meant by the words in-licensing deals. This type of deal and the reasons for making it (which are both specified in the provided source but which did not make it into the proposed claim) should be delineated. Furthermore, the claim sentence uses the word "now", which is deprecated. See WP:AWW.
  5. ^ This part of the edit request proposal requires clarification because it is unclear what is meant by the words additional programs.
  6. ^ This claim was added both because the programs were explained as "therapy" and because the language of the claim indicates that it was a deal which had already been achieved (rather than an announced future acquisition). However, as the description of what particular therapies were added was vague, the {{which}} inline template was added to the claim. As the information contained in the reference was based on a press release, the {{cite press release}} templates were used in both instances.

Proposed changes with clarifications[edit]

I have a COI with this company as an employee, but would like to request the following changes:

Clarification for Editor note 3: "This part of the edit request proposal requires clarification because it is unclear what is meant by the words primary endpoint."

  • Instead of "Axovant was developing it as a treatment for Lewy body dementia, but discontinued its development following the completion of a clinical trial that did not meet its primary endpoint."
  • Suggest change to read: "Axovant was developing it as a treatment for Lewy body dementia[1], but discontinued its development following the completion of a clinical trial that did not clearly show the expected effect[2][3]."

Clarification for Editor note 4: "This part of the edit request proposal requires clarification because it is unclear what is meant by the words in-licensing deals. This type of deal and the reasons for making it (which are both specified in the provided source but which did not make it into the proposed claim) should be delineated. Furthermore, the claim sentence uses the word "now", which is deprecated. See WP:AWW."

  • Instead of "Since joining the company as CEO, Pavan Cheruvu has made a pivot for the company into gene therapies, with a series of in-licensing deals. The first, a gene therapy now known as AXO-Lenti-PD to treat Parkinson’s disease, was licensed from Oxford Biomedica in June 2018."
  • Suggest change to read: "Since joining the company as CEO, Pavan Cheruvu has made a pivot for the company into gene therapies, with a series of acquisitions of product candidates from other companies. The first, a gene therapy known as AXO-Lenti-PD to treat Parkinson’s disease, was acquired from Oxford Biomedica in June 2018 [4][5]."

Clarification for Editor note 5: "This part of the edit request proposal requires clarification because it is unclear what is meant by the words additional programs."

  • Instead of "In July 2018, Axovant announced a second deal with Benitec for the rights to a gene therapy to treat oculopharyngeal muscular dystrophy (OPMD), along with five additional programs to treat conditions such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia."
  • Suggest change to read: "In July 2018, Axovant announced a second deal with Benitec for the rights to a gene therapy to treat oculopharyngeal muscular dystrophy (OPMD), along with five additional gene therapy programs to treat conditions such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia[6]. In December 2018, Axovant added two additional gene therapy programs to treat GM1 gangliosidosis and Tay-Sachs and Sandhoff diseases [7][8].

Clarification for Editor note 6: "This claim was added both because the programs were explained as "therapy" and because the language of the claim indicates that it was a deal which had already been achieved (rather than an announced future acquisition). However, as the description of what particular therapies were added was vague, the [which?] inline template was added to the claim. As the information contained in the reference was based on a press release, the (Press release). {{cite press release}}: Missing or empty |title= (help) templates were used in both instances"

  • Add ", AXO-AAV-GM1 and AXO-AAV-GM2," between "programs" and "to" in the last sentence, as shown in previous clarification.

144.121.125.3 (talk) 18:06, 30 January 2019 (UTC)[reply]

References

  1. ^ Grover, Natalie (28 Apr 2016). "Acadia drug approval could clear way for Axovant dementia therapy". Reuters.
  2. ^ Taylor, Nick Paul (10 December 2018). "Axovant dumps nelotanserin in retreat from small molecule R&D". FierceBiotech.
  3. ^ Terry, Mark (10 December 2018). "Axovant Abandons Another Dementia Drug After Failed Trial". BioSpace.
  4. ^ Terry, Mark (6 June 2018). "Axovant Licenses Gene Therapy for Parkinson's Disease from Oxford BioMedica". BioSpace.
  5. ^ Garde, Damian (6 June 2018). "Months after a monstrous blowup, a closely watched biotech sets its sights on gene therapy". STAT News. {{cite news}}: Italic or bold markup not allowed in: |newspaper= (help)
  6. ^ Carroll, John (9 July 2018). "Focused on rebuilding the pipeline, Axovant's new crew assembles another preclinical gene therapy deal". Endpoints.
  7. ^ Keown, Alex (14 December 2018). "Axovant Licenses Two Gene Therapies Aimed at Tay-Sachs and Sandhoff Disease". BioSpace.
  8. ^ Taylor, Nick Paul (14 December 2018). "Axovant buys more gene therapies, setting it up for a busy 2019". FierceBiotech.

Reply 29-JAN-2019[edit]

  Clarification requested  

  • Thank you for clarifying the language and phrasing used in these claims.
  • It is clear from the meaning which you have provided in 2 out of 4 of these claims that the information being projected here originates from company issued press releases which are promoting the business relationships behind certain treatments. In each of those circumstances what is being announced here are deals — business relationships entered into, to advance the company's product lineup.
  • This would be important information if the products being announced were notable on their own in some way. Unfortunately, none of the announcements made here indicate any substantial information regarding these products themselves, or when they do, they announce only that a product has failed in some way, its intended actions. All the other announcements advertise hope for their products. An announcement of hope is not notable.[a]
  • What is desired for the article would be substantive information provided on the progress of these treatments[b] coming from reliable secondary sources unconnected to either the company or the industry, in order to guarantee a WP:NPOV in their coverage.
  • It is not known what desired remedies are being proposed in order to address note 6. Kindly phrase your proposal verbatim in the form of "Please change x to y using z".

Regards,  Spintendo  21:46, 30 January 2019 (UTC)[reply]

Notes

  1. ^ My use of the term notable here is not connected to the Wikipedia article creation requirement of notability, which exists separately from content requirements.
  2. ^ This type of information would be expected years after a therapeutic agent was acquired in order to better account for its abilities.

Name Change for Axovant Sciences[edit]

I am a COI editor requesting that the page name and all subsequent references to the name be changed from Axovant Sciences Ltd to Axovant Gene Therapies Ltd. The company has officially changed its name as of March, as shown in these references. I know someone else tried to make this change himself in February and the change had not yet gone into effect - but now it has. I appreciate help with this matter. FinalFrontier.003 (talk) 08:12, 2 May 2019 (UTC)[reply]

Name Change References:

Reply 2-MAY-2019[edit]

  Please use WP:RMCM  

  • While the company's webpage header material references the newer name, the company still refers to itself as Axovant Sciences in the footer of these pages, where it states "© 2019 Axovant Sciences, Inc.". As a webpage's footer area is usually the location for links to important legal statements, notices, and other declarations, the name presented in that area is often taken to be the legitimate name of the company as opposed to whichever name is presented in company graphics elsewhere on the page.
  • Please note that the decision to move an article to a new name is also often based not on what the company states is the new name, but rather, what a preponderance of sources refer to the company as (See WP:COMMONNAME). In light of this, and owing to the webpage's ambiguity, the request to change the article's title should be submitted using the {{requested move}} template specifically as a controversial move request process requiring discussion amongst the wider community.
  • A controversial requested move typically takes about 7 days to complete.
  • Before taking this step, please ensure that you are well acquainted with the requested move process by thoroughly reviewing its procedures.
  • More information can be found at requested moves.
    Regards,  Spintendo  08:41, 2 May 2019 (UTC)[reply]

Proposed updates based on rebrand[edit]

To reflect the fact that the company has rebranded,[1] I propose the name of this page be changed to Sio Gene Therapies and the logo should reflect that change as well.

Lifescience2017 (talk) 18:39, 9 February 2021 (UTC)[reply]

References

  1. ^ Gelman, Max. "'We're not a vant': Axovant seeks to forget the past as the company rebrands to Sio Gene Therapies".
Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:Sio_Gene_Therapies&oldid=1205312416"